OA12969A - Combination for the treatment of ADHD. - Google Patents

Combination for the treatment of ADHD. Download PDF

Info

Publication number
OA12969A
OA12969A OA1200500174A OA1200500174A OA12969A OA 12969 A OA12969 A OA 12969A OA 1200500174 A OA1200500174 A OA 1200500174A OA 1200500174 A OA1200500174 A OA 1200500174A OA 12969 A OA12969 A OA 12969A
Authority
OA
OAPI
Prior art keywords
azabicyclo
substituted
carboxamide
alkyl
oct
Prior art date
Application number
OA1200500174A
Other languages
English (en)
Inventor
Donn Gregory Wishka
Vincent Edward Groppi Jr
Eric Jon Jacobsen
Jason Kenneth Myers
David Walter Piotrowski
Bruce Nelsen Rogers
Daniel Patrick Walker
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of OA12969A publication Critical patent/OA12969A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Liquid Crystal Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
OA1200500174A 2002-12-11 2003-11-28 Combination for the treatment of ADHD. OA12969A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43258602P 2002-12-11 2002-12-11

Publications (1)

Publication Number Publication Date
OA12969A true OA12969A (en) 2006-10-13

Family

ID=32507968

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200500174A OA12969A (en) 2002-12-11 2003-11-28 Combination for the treatment of ADHD.

Country Status (23)

Country Link
US (1) US20050107425A1 (fr)
EP (1) EP1572300A1 (fr)
JP (1) JP2006510663A (fr)
KR (1) KR20050085538A (fr)
CN (1) CN1735441A (fr)
AP (1) AP2005003336A0 (fr)
AU (1) AU2003283656A1 (fr)
BR (1) BR0317229A (fr)
CA (1) CA2509142A1 (fr)
CO (1) CO5700801A2 (fr)
CR (1) CR7868A (fr)
EA (1) EA200500783A1 (fr)
EC (1) ECSP055852A (fr)
HR (1) HRP20050522A2 (fr)
IS (1) IS7858A (fr)
MA (1) MA27606A1 (fr)
MX (1) MXPA05006336A (fr)
NO (1) NO20053185L (fr)
OA (1) OA12969A (fr)
PL (1) PL377552A1 (fr)
TN (1) TNSN05158A1 (fr)
WO (1) WO2004052461A1 (fr)
ZA (1) ZA200504338B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
GB0310867D0 (en) * 2003-05-12 2003-06-18 Novartis Ag Organic compounds
CA2560741C (fr) 2004-03-25 2013-08-06 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, et leur preparation et leurs utilisations
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
WO2008083442A1 (fr) * 2007-01-10 2008-07-17 Brc Operations Pty Limited Procédé pour la formulation de médicaments mixtes contre tdah
JP2010522766A (ja) * 2007-03-28 2010-07-08 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー １１ベータ−ｈｓｄ１活性化合物
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
BRPI0908098A2 (pt) * 2008-02-19 2015-08-18 Adolor Corp Beloxepina, composição, métodos para tratar dor em um mamífero, para inibir a recaptação de ne, para antagonizar um receptor de 5ht2 e para tratar um distúrbio em um paciente que é responsivo ao tratamento com um composto nri e com um composto antagonista de 5ht2
KR20110088575A (ko) 2008-11-21 2011-08-03 하이 포인트 파마슈티칼스, 엘엘씨 아다만틸 벤즈아미드 화합물
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
UY33389A (es) 2010-05-17 2011-12-30 Mitsubishi Tanabe Pharma Corp Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidrato
US8513430B2 (en) 2010-07-27 2013-08-20 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators
RU2017136693A (ru) 2012-05-08 2019-02-08 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
WO2014078568A1 (fr) 2012-11-14 2014-05-22 The Johns Hopkins University Méthodes et compositions pour le traitement de la schizophrénie
KR102629135B1 (ko) 2021-08-19 2024-01-29 단국대학교 천안캠퍼스 산학협력단 Kds2010을 유효성분으로 포함하는 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물
KR20230027862A (ko) 2021-08-20 2023-02-28 단국대학교 천안캠퍼스 산학협력단 주의력결핍 과잉행동장애의 진단을 위한 gat-3의 용도
KR102597711B1 (ko) 2021-08-20 2023-11-06 단국대학교 천안캠퍼스 산학협력단 Snap5114을 유효성분으로 포함하는 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물
WO2023022269A1 (fr) 2021-08-20 2023-02-23 단국대학교 천안캠퍼스 산학협력단 Composition pharmaceutique pour prévenir ou traiter un trouble déficitaire de l'attention avec hyperactivité

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor

Also Published As

Publication number Publication date
MA27606A1 (fr) 2005-11-01
CN1735441A (zh) 2006-02-15
ECSP055852A (es) 2005-09-20
KR20050085538A (ko) 2005-08-29
NO20053185D0 (no) 2005-06-29
EA200500783A1 (ru) 2005-12-29
JP2006510663A (ja) 2006-03-30
BR0317229A (pt) 2005-11-01
TNSN05158A1 (fr) 2007-05-14
ZA200504338B (en) 2006-07-26
CA2509142A1 (fr) 2004-06-24
MXPA05006336A (es) 2005-08-26
WO2004052461A1 (fr) 2004-06-24
AU2003283656A1 (en) 2004-06-30
PL377552A1 (pl) 2006-02-06
IS7858A (is) 2005-05-23
CR7868A (es) 2005-07-08
US20050107425A1 (en) 2005-05-19
NO20053185L (no) 2005-08-17
EP1572300A1 (fr) 2005-09-14
CO5700801A2 (es) 2006-11-30
HRP20050522A2 (en) 2005-12-31
AP2005003336A0 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
AU2003279492A1 (en) Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
HRP20050522A2 (en) Combination for the treatment of adhd
EP1432707B1 (fr) Composes d'heteoraryle fusionne substitues par azabicyclo utiles pour le traitement de maladies
AU2004206107A1 (en) Treatment of diseases with alpha-7 nach receptor full agonists
WO2003070732A1 (fr) Carboxamides hetero-aromatiques n-pontes bicycliques condenses destines au traitement de maladies
CA2460075A1 (fr) 7-aza`2.2.1!bicycloheptanes substitues pour traitement de maladies
JP2006506395A (ja) ＣＮＳ疾患の治療のための、α７ニコチンアゴニスト活性及び５ＨＴ３アンタゴニスト活性を有する化合物
WO2004039366A1 (fr) Agonistes nicotiniques de l'acetylcholine dans le traitement du glaucome et d'une neuropathie de la retine
AU2002339957A1 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease